Acepix Biosciences

Executive Summary

Acepix Biosciences is a privately held life science tools and services company headquartered in Cambridge, Massachusetts, specializing in high-quality biospecimens and histopathology services for oncology and immunology research. Founded in 2015, the company provides FFPE (formalin-fixed, paraffin-embedded) cell pellets, tissue arrays, and associated services to support biomarker discovery, assay validation, and translational research. By offering standardized, well-characterized materials, Acepix enables pharmaceutical and biotech partners to accelerate preclinical and diagnostic development. As a pre-clinical stage company, Acepix operates in a niche but essential segment of the drug development ecosystem, serving the growing demand for reproducible and high-quality tissue samples in precision medicine. While the company has not disclosed funding rounds or valuation, its focus on quality and specialization positions it as a reliable partner for research organizations seeking to de-risk their biomarker and diagnostic programs.

Upcoming Catalysts (preview)

• Q3 2026Expansion of Product Catalog with New Tissue Arrays70% success
• Q4 2026Strategic Partnership with a Major Pharmaceutical Company40% success
• H1 2027Achievement of CLIA or CAP Accreditation50% success